ArticlePloS one2015
A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- Development of gemcitabine-modified multimodal miR-129 mimic as a novel therapeutic in non-small cell lung cancer.Molecular therapy. Nucleic acids · 2026Article
- Tumour-specific activation of a tumour-blood transport improves the diagnostic accuracy of blood tumour markers in mice.EBioMedicine · 2024Article
- RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions.Cancer medicine · 2024Review
- Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.International journal of nanomedicine · 2021Article
- Review
- Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors.Molecular pharmaceutics · 2020Article
- Recombinant cell-permeable HOXA9 protein inhibits NSCLC cell migration and invasion.Cellular oncology (Dordrecht, Netherlands) · 2019Article
- Tumor-Penetrating Peptide Enhances Antitumor Effects of IL-24 Against Prostate Cancer.Translational oncology · 2019Article
- iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers.Journal of oncology · 2019Review
- Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability.Scientific reports · 2018Article
- Peptides as drug delivery vehicles across biological barriers.Journal of pharmaceutical investigation · 2018Article
- Overcoming key biological barriers to cancer drug delivery and efficacy.Journal of controlled release : official journal of the Controlled Release Society · 2017Review
- iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery.Nanomedicine (London, England) · 2017Article
- Tumor penetrating peptides for improved drug delivery.Advanced drug delivery reviews · 2017Review
- Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.eLife · 2017Article
- Doxorubicin-triggered self-assembly of native amphiphilic peptides into spherical nanoparticles.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, comprising approximately 75-80% of all lung cancers. Gemcitabine is an approved chemotherapy drug for NSCLC. The objective of this study was to develop a novel strategy to improve the therapeutic efficacy of Gemcitabine for NSCLC by the co-administered iRGD peptide. We showed that the rates of positive expression of αvβ3, αvβ5 and NRP-1 in the A549 cell line were 68.5%, 35.3% and 94.5%, respectively. The amount of Evans Blue accumulated in the tumor of Evans Blue+iRGD group was 2.5 times that of Evans Blue group. The rates of growth inhibition of the tumors of the iRGD group, the Gemcitabine group and the Gemcitabine+iRGD group were 8%, 59.8% and 86.9%, respectively. The results of mechanism studies showed that PCNA expression in the Gemcitabine+iRGD group decreased 71.5% compared with that in Gemcitabine group. The rate of apoptosis in the Gemcitabine+iRGD group was 2.2 time that of the Gemcitabine group. Therefore, the tumor-penetrating Peptide iRGD can enhance the tumor-penetrating ability and therapeutic efficacy of Gemcitabine in the A549 xenograft. The combined application of Gemcitabine with iRGD may be a novel strategy to enhance the clinical therapeutic efficacy of Gemcitabine in patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.